{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:24Z","timestamp":1792103604604,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK 205715"],"award-info":[{"award-number":["GSK 205715"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40262-021-00988-1","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T10:10:36Z","timestamp":1613729436000},"page":"887-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)"],"prefix":"10.1007","volume":"60","author":[{"given":"Shuying","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Sule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Peachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"10","key":"988_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3109\/02770903.2015.1056350","volume":"52","author":"DI Bernstein","year":"2015","unstructured":"Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, et al. Fluticasone furoate (FF)\/vilanterol (100\/25 mcg or 200\/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2015;52(10):1073\u201383.","journal-title":"J Asthma."},{"issue":"2","key":"988_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","volume":"55","author":"LK Lee","year":"2018","unstructured":"Lee LK, Obi E, Paknis B, Kavati A, Chipps B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018;55(2):208\u201319.","journal-title":"J Asthma."},{"issue":"1","key":"988_CR3","doi-asserted-by":"publisher","first-page":"1701126","DOI":"10.1183\/13993003.01126-2017","volume":"51","author":"I Sulaiman","year":"2018","unstructured":"Sulaiman I, Greene G, MacHale E, Seheult J, Mokoka M, D\u2019Arcy S, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1):1701126.","journal-title":"Eur Respir J."},{"issue":"3","key":"988_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","volume":"56","author":"J Davis","year":"2019","unstructured":"Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS\/LABA: a real-world study. J Asthma. 2019;56(3):332\u201340.","journal-title":"J Asthma."},{"key":"988_CR5","unstructured":"GINA. Global Initiative for Asthma guidelines 2020. https:\/\/ginasthma.org\/. Accessed 3 Aug 2020."},{"key":"988_CR6","unstructured":"GSK. Trelegy Ellipta US prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209482s000lbl.pdf. Accessed 8 Jul 2020."},{"issue":"1","key":"988_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, Boulet L, Edwards D, Fowler A, et al. Efficacy and safety of once-daily single-inhaler triple therapy (fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma: a double-blind, randomised phaseIIIA trial (CAPTAIN study). Lancet Respir Med. 2021;9(1):69\u201384.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"988_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CP202438","volume":"54","author":"A Allen","year":"2016","unstructured":"Allen A, Siederer S, Yang S. Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. Int J Clin Pharmacol Ther. 2016;54(4):269\u201381.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"1","key":"988_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13318-016-0331-8","volume":"42","author":"S Yang","year":"2017","unstructured":"Yang S, Lee L, Pascoe S. Population pharmacokinetics modeling of inhaled umeclidinium for adult patients with asthma. Eur J Drug Metab Pharmacokinet. 2017;42(1):79\u201388.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"1","key":"988_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40262-019-00794-w","volume":"59","author":"R Mehta","year":"2020","unstructured":"Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA. Population pharmacokinetic analysis of fluticasone furoate\/umeclidinium bromide\/vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2020;59(1):67\u201379.","journal-title":"Clin Pharmacokinet."},{"key":"988_CR11","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease GOLD Report. 2020. https:\/\/goldcopd.org\/gold-reports\/. Accessed 3 Aug 2020."},{"issue":"4","key":"988_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401\u201321.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"2","key":"988_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J."},{"key":"988_CR14","first-page":"15","volume":"10","author":"R Mehta","year":"2015","unstructured":"Mehta R, Hardes K, Brealey N, Tombs L, Preece A, Kelleher D. Effect of severe renal impairment on umeclidinium and umeclidinium\/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. Int J Chron Obstruct Pulmon Dis. 2015;10:15\u201323.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"4 Pt 1","key":"988_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1164\/ajrccm.161.4.9902063","volume":"161","author":"B Korotzer","year":"2000","unstructured":"Korotzer B, Ong S, Hansen JE. Ethnic differences in pulmonary function in healthy nonsmoking Asian\u2013Americans and European\u2013Americans. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1101\u20138.","journal-title":"Am J Respir Crit Care Med."},{"issue":"7","key":"988_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-014-0143-4","volume":"53","author":"N Goyal","year":"2014","unstructured":"Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2014;53(7):637\u201348.","journal-title":"Clin Pharmacokinet."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-00988-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T01:04:56Z","timestamp":1625187896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-00988-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-00988-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by the GlaxoSmithKline (study number GSK 205715), NCT02924688.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SY, NS, AF, and GP are all employees of GlaxoSmithKline (GSK) and own stocks and shares in the company. LAL was an employee of GSK at the time of this study. GP also owns stocks and shares in Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, and applicable country-specific regulatory requirements. The protocol received approval from applicable central or local Institutional Review Boards or independent Ethics Committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants before participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymized individual participant data and study documents can be requested for further research from .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the manuscript, and have given final approval for the version to be published. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. SY, LL, and GP were involved in the conception and design of the study and the data analysis and interpretation. AF and NS were involved in the data analysis and interpretation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}